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Leukocytes and the natural history of deep vein thrombosis:
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Kings College London, BHF Centre of Research Excellence & NIHR Biomedical Research Centre
at Kings Health Partners, Academic Department of Surgery, St Thomas' Hospital, London, UK.
Abstract
Observational studies have shown that inflammatory cells accumulate within the thrombus and
surrounding vein wall during the natural history of venous thrombosis. More recent studies have
begun to unravel the mechanisms that regulate this interaction and have confirmed that thrombosis
and inflammation are intimately linked. This review outlines our current knowledge of the
complex relationship between inflammatory cell activity and venous thrombosis and highlights
new areas of research in this field. A better understanding of this relationship could lead to the
development of novel therapeutic targets that inhibit thrombus formation or promote its resolution.
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Introduction
Deep Vein Thrombosis (DVT) is a common condition affecting 1-2% of the population with
an annual incidence of 1 in 5001. DVT can lead to death through pulmonary embolism (PE)
and many patients subsequently suffer from venous reflux, which can lead to the post-
thrombotic syndrome (PTS). This condition is characterised by pain, swelling and chronic
leg ulceration. Around one quarter of patients develop PTS within 1 year of the episode of
thrombosis2. DVT is therefore potentially fatal, can cause significant patient morbidity and
has become an economic burden for health care services in the developed world.
Treatments for DVT such as anticoagulation prevent thrombus propagation and extension,
but have little effect on existing thrombi, which resolve naturally through a process of
organisation and vein recanalisation3. Rapid natural resolution is associated with less
valvular damage, reduced venous hypertension, and fewer post thrombotic complications4-6.
Treatments that remove thrombus rapidly such as thrombolysis and mechanical removal are,
however, associated with increased morbidity, have significant haemorrhagic side effects
and increase the risk of re-thrombosis7. An organised thrombus (usually those which have
been present for more than 14 days), a history of stroke, or a recent operation, are
contraindications to the use of thrombolytic therapy8. Alternative forms of treatment, which
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prevent thrombosis or accelerate natural thrombus resolution without haemorrhagic side
effects, would therefore be attractive. It is likely that these will only be developed from a
better understanding of the mechanisms that regulate thrombus formation and its resolution.
There is increasing evidence that inflammatory processes and DVT are intimately linked.
This review outlines our current understanding of the complex relationship between
inflammatory cell activity and venous thrombosis and highlights new areas of research in
this field.
Venous thrombus formation
A triad of vessel wall injury, venous stasis and blood hypercoagulability have historically
been considered to predispose to venous thrombosis9. Venous thrombi arise in both the vein
valve pockets and dilated sinuses of the lower limbs, are fibrin and red cell rich, and form on
the surface of the endothelium10-12. They have a laminar structure consisting of layers of
platelets, leukocytes and fibrin (‘lines of Zahn’) that encompass the main erythrocyte mass.
This is unlike the amorphous structure of a ‘blood clot’, which consists predominantly of
erythrocytes within a fine fibrin mesh3.
Studies in the 1970s using radiolabeled leukocytes have shown uptake of white blood cells
into venous thrombi13, while accumulation of polymorphonuclear neutrophils (PMNs) on
the abluminal side of the endothelium following occlusion of canine veins, first led to the
speculation that ‘white-cell’ induced damage to the endothelium may be a contributing
factor to venous thrombosis in man14 (Fig 1i). Exposure of the collagen rich wall is said to
lead to platelet aggregation and further leukocyte sequestration, which results in a nidus for
thrombus propagation15, 16. C-reactive protein (CRP), an inflammatory marker, has been
shown to increase in patients suffering with DVT17. Inflammation is therefore considered an
important mechanism for venous thrombus formation.
Inflammation and the endothelium
The formation, propagation, and dissolution of venous thrombi represents a balance between
coagulation and innate protective mechanisms, specifically the circulating inhibitors of
coagulation (e.g. tissue factor pathway inhibitor, thrombomodulin, protein C, plasminogen
activator inhibitors) and promoters of fibrinolysis (e.g. plasminogen activators)9.
Endothelial ‘microtears’ containing leukocytes have been demonstrated by electron
microscopy in the deep veins following hip surgery in dogs18, leading to the suggestion that
these may be the nidus for venous thrombus formation. Others have, however, found no
major overt damage to the endothelium at sites of thrombosis in man10. Crushing the vein to
cause endothelial damage does not lead to the formation of experimental venous thrombi19
and scanning electron microscopy reveals minimal endothelial damage immediately after
thrombus formation in the rat20. Disturbance of the endothelium by mechanical (e.g. stretch
or surgery) or chemical means (e.g. sepsis) can, however, cause activation of the
endothelium resulting in increased expression of procoagulant proteins such as tissue factor
(TF)21, cytokines and surface adhesion of molecules that promote leukocyte adhesion and
initiate thrombosis22 (Fig 1i). Genetic knock-out of the adhesion molecules E- and P-
selectin results in reduced thrombus size, and this is associated with altered leukocyte
accumulation in the surrounding vein wall23. Neutralising P-selectin glycoprotein ligand-1
(PSGL-1) also reduces local inflammation and thrombus size, and could be a potential
treatment for the prevention of DVT in the future24.
Circulating TF, in the form of microparticles (MPs) released by activated leukocytes,
accumulate in areas of stasis such as the vein valve pockets21. Leukocyte MPs that express
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PSGL-1, bind to P-selectin both on platelets and activated endothelial cells25, 26, and this
source of TF could sustain the production of thrombin on the forming thrombus, promoting
its propagation27. The relative contribution of leukocyte MPs to venous thrombosis is,
however, not clear, as adoptive transfer of bone marrow from mice expressing low levels of
TF, into wild types does not inhibit thrombus formation28. It appears that the vessel wall is
the most important source of TF that promotes thrombogenesis28, and therefore activation of
the endothelium may be pivotal in the inflammatory processes that lead to thrombosis.
Polymorphonuclear neutrophils (PMNs)
PMNs are found in large numbers within the early venous thrombus20, 29. Recent studies on
the mechanisms of PMN recruitment to sites of sterile inflammation have revealed that
intravascular danger signals, including the activation of the Nlrp3 inflammasome, generation
of a chemokine gradient and release of formyl-peptide signals, act as a guide to these sites30.
PMN adhesion to endothelium is mediated by interactions between the integrin αMβ2
(Mac1) and its endothelial ligand intracellular adhesion molecule-1 (ICAM-1)30 (Fig 1ii).
Whether a similar mechanism is involved in PMN accumulation during venous thrombosis,
remains to be determined though it appears that the thrombogenic effects of
antiphospholipid antibodies are mediated in part by ICAM-131.
Aside from the formation of a nidus for thrombus propagation, recent data have emerged
which suggest that recruited PMNs may initiate thrombosis through the formation of
neutrophil extracellular traps (NETs)32 (Fig 1iii). These extracellular DNA fibres, which
comprise of histones and neutrophil antimicrobial proteins, form following a cell death
programme in response to inflammatory stimuli (e.g. IL-8, reactive oxygen species) from
cells in vitro33-35, and have been linked to small vessel vasculitis36 and pre-eclampsia37.
DNA traps appear in the plasma and thrombus following induction of DVT in a baboon
model and could provide a scaffold for thrombus formation, though their precise mechanism
of action remains to be elucidated32.
The role of PMNs in the natural history of the venous thrombus is however complex.
Selective antibody depletion of PMNs in a rat stasis model, led to larger venous thrombi
suggesting that PMNs are not required for thrombus formation, but may be important in
removal of forming thrombus38 (Fig 2). A similar finding was not, however, demonstrated
in a murine model and CXCR2-dependent thrombus resolution appeared independent of the
CXCR2 primary effector leukocyte, the PMN39. PMNs also show both pro and
antifibrinolytic activity in an ex vivo thrombosis model40. These paradoxical results could,
at least in part, be explained from functional heterogeneity in the neutrophil compartment.
Circulating PMNs, express a variety of membrane receptors including CD11b, CD16,
CXCR1, C5aR, FcγRII and TLR4. Differential expression of these receptors is known to
confer functionally distinct roles for PMNs following LPS-induced inflammation in man;
activated, differentiated PMNs mediate tissue damage41. Future studies into the role of the
PMNs in venous thrombosis should consider the functional heterogeneity of this cell type. It
is possible that given certain environmental cues, specific subsets of PMNs contribute to
thrombus formation, while other distinct PMNs may be more important for its resolution.
Red blood cells, inflammation and thrombosis
The contribution of red blood cells (RBCs) to venous thrombosis remains poorly
understood, despite their abundance in the early venous thrombus and their contribution to
platelet rich arterial thrombi42. The cytoplasm of RBCs is rich in iron, which when released
into the circulation is highly inflammatory because of its oxidative effects on the
endothelium. It has been hypothesised that reactive oxygen species, produced by leukocytes
and vessel wall at the nidus of thrombosis, oxidises haemoglobin in RBCs that become
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trapped by cross-linked fibrin forming at this point. This results in the formation of
methaemoglobin (metHb) containing Fe3+. The release of Fe3+ leads to a cascade of RBC
lysis that results in further endothelial dysfunction43 and thrombus propagation (Fig 1iv).
Natural antioxidants, such as hemeoxygenase-1 (HO-1)-derived carbon monoxide and
superoxide dismutase, produced by cells within the vessel wall and thrombus, may limit
these inflammatory effects. This putative mechanism by which RBCs may influence the
development of venous thrombi is supported by the finding that propagation of venous
thrombosis is enhanced in HO-1−/− mice44, while specific genetic variants (long GT-repeat
alleles) in the HO-1 gene appear to confer increased risk of recurrent venous
thromboembolism in man45.
The inflammatory nature of the early, oxidised, RBC-rich thrombus has been exploited in
the development of imaging methods to identify acute venous thrombi in man46. MetHb
exerts paramagnetic properties resulting from its five unpaired electrons, which shortens the
nuclear magnetic resonance longitudinal relaxation time (T1) of the thrombus. It is therefore
possible to accurately demonstrate contrast between young thrombi and surrounding tissues
using MRI47. Advances in technology have allowed the rapid quantification of T1 relaxation
time, suitable for a clinical setting48. When scanning thrombus in the same patient, T1
relaxation times are short in the young thrombus (800ms), but return to that of blood
(1300ms) by six months, presumably because of the phagocytic action of cells that
accumulate within the thrombus as it resolves and take up iron49. The in vivo
characterisation of DVT in man, without the need for a contrast agent, could be used to
predict clinical outcome following DVT and guide management. MRI identification of fresh
thrombi, could help stratify patients into whom thrombolysis has the greatest potential. It
could also act as a surrogate outcome measure when testing the efficacy of novel treatments
in clinical trials. Validation of the relationship between T1 relaxation times and thrombus
structure by comparing MR images with histology is, however, still required.
Venous thrombus resolution
Natural thrombus resolution is characterised by tissue organisational processes (including
neovascularisation) reminiscent of those seen during wound healing3, 9. Organisation
ultimately leads to varying degrees of thrombus resolution with consequent recanalisation of
the vein lumen10, 11. As in wound healing, there is a temporal change in the leukocyte
composition of the thrombus both in terms of cell types and their numbers during
resolution20, 29 (Fig 2). The majority of the leukocytes in the early thrombus appear to be
PMNs, which may have a role in vein wall remodeling50, while macrophages predominate
in the later stages of resolution and are likely to be the most important effector cells of this
process51-53. The chemotactic proteins interleukin-8 (IL-8) and Monocyte chemotactic
protein-1 (MCP-1) that are produced within the thrombus, may be important stimuli for the
recruitment of these cells54, 55. Our studies of thrombosis in mice with severe combined
immunodeficiency (SCID) suggest that lymphocytes have no role in either thrombus
formation or its resolution56.
Putative functions of inflammatory cells during thrombus resolution
The role of inflammation, and specifically leukocytes such as PMNs and the monocyte/
macrophage, during thrombus resolution is not completely understood (Fig2). Studies in
mice lacking the ets transcription factor Pu.1 suggest that inflammatory cell activity may not
be a prerequisite for tissue repair57. Nevertheless, leukocytes comprise a significant
proportion of the cells in the thrombus, and, interventions that lead to alterations in their
accumulation lead to significant effects on subsequent thrombus resolution.
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There is increased plasminogen activator content, both tissue-type (tPA) and urokinase-type
(uPA) that co-localises with macrophages in thrombus formed in the rat58, 59. This has led to
the speculation that fibrinolysis is important for thrombus resolution. Deletion of the tissue-
type plasminogen activator gene (tPA−/−), however, has no effect on this process51. By
contrast, deletion of the urokinase-type plasminogen activator gene (uPA−/−), prevents
resolution and is associated with reduced macrophage numbers in the thrombus51. Adoptive
transfer of wild-type bone marrow into uPA−/− mice rescues normal resolution51, 60-62,
while upregulation of uPA in macrophages enhances this process56. Urokinase - urokinase
receptor (uPAR) interaction is commonly thought to be a major regulatory mechanism for
cell migration. Plasmin generation at the cell surface activates other proteases such as matrix
metalloproteinases (MMPs, including MMP-2 and MMP-9) that degrade extracellular
matrix, facilitating cell migration60-62. These data lead us to speculate that monocyte-
associated urokinase-activity is important for venous thrombus resolution.
Neovascular channels appear around the thrombus wall junction and within the thrombus as
resolution proceeds3, 10, 11. Histological studies in rodent models suggest that these
channels are derived from the vein wall3, and they may also be derived from cells residing in
the thrombus63. We have found that enhancing the levels of either VEGF alone, or
simultaneously with a number of other angiogenic factors through upregulation of HIF1a
within the thrombus, enhances its resolution64-67. These outcomes are linked to macrophage
accumulation within the thrombus, which perhaps act as ‘cellular chaperones’ as recently
described in the development of the vascular network68.
Leukocyte signaling during venous thrombus resolution
Fibrin(ogen) and its degradation products are present in abundance in the thrombus51, 69.
These molecules are able to stimulate recruitment and activation of leukocytes, to produce
cytokines (TNFα and IL1β) and chemokines (IL8 and MCP1) in inflammatory settings70, 71
and promote phagocytosis and cell migration in vitro72. Interaction of the fibrinogen γ chain
residue 390-396 with Mac1 is thought to be an important pathway by which these molecules
influence leukocyte activity72. Mononuclear cells may also interact with fibrinogen to
produce chemokines through a TLR4 dependent mechanism73. Examination of thrombus
formation and resolution in mice that carry mutations such as Fibγ 390-396A, may provide
new insights into the role of fibrin(ogen) and its degradation products in the natural history
of venous thrombi.
More recently, data have emerged that have provided new insights into the signaling
mechanisms that regulate the functions of leukocytes during venous thrombus resolution.
Deletion of toll-like receptor 9 gene (TLR9−/−) impairs resolution assessed at days 2 and 8
after induction, despite an increase in the numbers of both PMNs and Mac2+ macrophages
in the thrombus74. These data suggest that TLR9 is important for leukocyte function during
thrombus resolution. This effect was independent of MyD88 signalling (a major TLR
signaling pathway), and was related to NOTCH ligand delta-like 4 pathways. TLR9−/− mice
have reduced thrombus neovascularisation and decreased levels of the Th1 inflammatory
cytokines IFNα, IL1α and IL2 in the vein wall, which appears to be important for venous
thrombus resolution52. Further investigation is required to elucidate the role of TLR9 and
MyD88 in later phases of thrombus resolution (beyond 8 days) and whether other TLRs are
involved.
Mononuclear phagocytes
Macrophage accumulation within the thrombus is a hallmark of resolving thrombus in both
man and experimental models3, 9, 49. Adoptive transfer experiments suggest that these cells
are derived from the bone marrow (BM)75, however macrophages that are not of BM origin,
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may also have a role in thrombus resolution51. Macrophages that accumulate in the
thrombus could be derived from cells that are resident within the vein wall, or may even
arise from the ‘splenic reservoir’ that has recently been described76. The relative
contribution of these sources for cells implicated in the resolution of venous thrombi
remains unknown.
Although it is generally thought that the accumulation of macrophages is dependent on the
recruitment of circulating monocytes, direct visualisation of these cells entering the
thrombus has yet to be demonstrated. Renewal of certain resident mononuclear cells
(microglia and Langerhans cells) in the steady state appears to be independent of BM77, 78.
Adult LCs self renew in situ and proliferate during inflammation79. A demonstration that
macrophages proliferate in the thrombus would change the current paradigm regarding the
nature of their accumulation.
The function of mononuclear cells in the thrombus also remains to be fully elucidated. As
they are phagocytic by definition, it seems reasonable to speculate that they contribute to the
clearance of cells, nucleotides and matrix proteins within the thrombus. These cells may also
promote fibrinolysis, are associated with angiogenesis and could regulate tissue
remodeling80-82 - processes seemingly beneficial for thrombus resolution. To add further
complexity, both monocytes and macrophages consist of heterogeneous populations of cells,
which appear to have distinct functions83.
Circulating monocyte subsets can be distinguished on the basis of their expression of surface
receptors84. Circulating ‘inflammatory’ monocytes, express Ly6C in the mouse, and are
recruited into tissue where they undergo activation in a pathogen dependent response84, 85.
In a model of spinal cord injury, recruitment of Ly6C+ monocytes appears important for
tissue repair86 and these monocytes may also contribute to the fraction of myeloid derived
suppressor cells (MDSCs) that promote tumour driven angiogenesis87. The contribution of
Ly6C+ monocytes in the formation and resolution of venous thrombosis has yet to be
established, but our previous studies suggest that recruitment of this subset may be
important for thrombus resolution. Impaired resolution occurs in Ccr2−/− mice52, 53, and
CCR2 is required for the exit of Ly6C+ monocytes from bone marrow88.
Ly6C− monocytes exhibit long range crawling over the endothelium of both arteries and
veins89. It has been hypothesised that they are involved in the surveying of the vasculature
and sensing of tissue damage such as dying or infected cells78, 90. In a model of myocardial
infarction, Ly6C+ monocytes initially accumulate in the healing myocardium and may digest
damaged tissue81. In a later reparative phase, Ly6C− monocytes predominate and are
suggested to be involved in tissue repair by inducing myofibroblast accumulation,
angiogenesis and collagen deposition81. The human equivalent of Ly6C− murine monocytes
(CD14dim monocytes), have recently been implicated in the pathogenesis of autoimmune
diseases such as lupus, and respond to viruses and nucleic acid-containing immune
complexes via a pro-in?ammatory TLR7-TLR8-MyD88-MEK pathway90. Whether these
patrolling cells have a role in venous thrombosis (initiation or resolution) remains to be
determined, although we speculate that their patrolling function makes them an ideal
candidate for the detection of endothelial dysfunction and possible initiation of coagulation.
When monocytes enter tissue they differentiate into macrophages91. Based on in vitro
studies, these cells have been tentatively classified by some into two main phenotypes: those
that promote inflammatory responses (M1 or classically activated – expressing
inflammatory mediators such as TNFα and NOS2); and those that attenuate inflammatory
responses (M2a-c or alternatively activated – expressing arginase, mannose receptor [MR]
and the transcription factors - Fizz1 and Ym1/2). Others consider dividing macrophage
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populations based on their immunological or trophic roles in response to granulocyte/
macrophage CSF (also known as CSF2) or macrophage CSF (also known as CSF1)
respectively80. A rigid classification of macrophages probably represents the extremes of a
continuous spectrum and may be too simplistic as these cells may exhibit characteristics of
more than one phenotype81. M2-like macrophages have, however, been reported in the
healing myocardium and injured skeletal muscle, where they are considered to be involved
in tissue repair and wound resolution92, 93.
Clinical trials involving the therapeutic targeting of macrophages in other vascular diseases
such as atherosclerosis has been largely unsuccessful94. This in part is because of a lack of
understanding of their function95. Their roles in venous thrombosis require investigation,
especially because different monocyte and macrophage phenotypes may have
complimentary and contrasting functions83. This could be achieved through the use of
functional reporter mice that express fluorescent proteins linked to cell specific genes96. We
are currently developing these tools to examine cellular functions in thrombus resolution.
Inflammation is a central mechanism in both the genesis and resolution of venous thrombi.
The temporal accumulation of leukocytes in the forming (PMNs) and resolving thrombus
(macrophages) is part of a dynamic ‘intravascular wound healing process’ that results in
either the early lysis of the thrombus, or its stabilisation and subsequent resolution.
Enhancing our understanding of the cellular and molecular pathways that mediate sterile
inflammation in the context of venous thrombosis, could lead to the development of novel
therapeutic targets for: i) prevention of deep vein thrombosis in a manner that does not
promote pathological bleeding; and ii) acceleration of natural thrombus resolution to reduce
the incidence of post thrombotic complications. These may be achieved through
developments in molecular and cellular imaging capable of delineating specific
inflammatory processes that are currently on the horizon.
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Fig 1. Inflammation in venous thrombogenesis
(i) Activation of the endothelium (EC - red cell) generates intravascular danger signals,
which guide leukocytes to areas of inflammation and induces tissue factor (TF) production.
(ii) Upregulation of adhesion molecules on endothelium mediate PMN recruitment while
tissue factor generates thrombin, activating platelet (Plt) deposition and converting
fibrinogen to cross-linked fibrin (Fb) that entraps the main red blood cell (RBC) mass. (iii)
PMN accumulation in the subendothelial layer and subsequent exposure of collagen (Col)
causes platelet aggregation and further PMN sequestration establishing a nidus for thrombus
formation (iii). PMN apoptosis in response to inflammatory stimuli releases neutrophil
extracellular traps (NETs, blue strands) that provide a scaffold for further RBC capture (iii).
Reactive oxygen species (ROS), released from the vessel wall and leukocytes, oxidise
haemoglobin (Hb) to methaemoglobin (MetHb, blue RBC). As trapped RBCs lyse, Fe3+
contained in metHb is released and induces further RBC lysis. This leads to a positive
feedback loop with increased areas of endothelial dysfunction resulting in thrombus
propagation (iv).
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Fig 2. Putative functions of leukocytes in venous thrombus resolution
Leukocytes accumulate in the venous thrombus during its resolution. Polymorphonuclear
neutrophils (PMN) predominate in the early stages of resolution with mononuclear
phagocytes (M?) predominating later. The origin of these cells appears to be from the bone
marrow (BM), however the contribution of tissue resident macrophages or cells derived
from the ‘splenic reservoir’, remains unknown. Leukocytes signal through a TLR9
mechanism and may be stimulated by fibrin(ogen) and its degradation products. They are
speculated to have a number of functions important for thrombus resolution.
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